| Human Immunodeficiency Virus |
| Recruiting | 4 | 50 | | | The University of New South Wales, National Heart Lung and Blood Institute, US National Institutes of Health | HIV
, Lipid metabolism, Glucose metabolism, Metabolic abnormality, Lipodystrophy, Cardiovascular disease | | | | |
ACTRN12612000732886: Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults. |
|
|
| Recruiting | 4 | 60 | | | St. Vincent's Hospital, Sydney | Hypercholesterolaemia associated with ritonavir-boosted protease inhibitor therapy in of HIV-infected adults | | | | |
| Recruiting | 4 | 80 | | | The University of New South Wales, National Heart Lung and Blood Institute, US National Institutes of Health | HIV
, Metabolic abnormality, Lipodystrophy, Cardiovascular disease | | | | |
ACTRN12611000816954: A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART): MARCH study |
|
|
| Recruiting | 4 | 560 | | | University of New South Wales, Kirby Institute, Pfizer Inc., a Delaware Corporation | HIV | | | | |
ACTRN12610001098022: ALTAIR - Alternative Antiretroviral Strategies: A Comparison of Three Initial Regimens |
|
|
| Active, not recruiting | 4 | 300 | | | The National Centre in HIV Epidemiology and Clinical Research, Gilead Sciences, Inc. | Human Immunodeficiency Virus - HIV, HIV+ treatment-naive patients | | | | |
ACTRN12609000881235: A randomised open-label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2-3 nucleoside reverse transcriptase inhibitors (NRTI) backbone versus ritonavir boosted lopinavir and raltegravir in participants virologically failing first-line non-nucleoside reverse transcriptase inhibitors (NNRTI)/2 NRTI therapy (the SECOND-LINE study). This study is for Human Immunodeficiency Virus (HIV) infection. |
|
|
| Active, not recruiting | 4 | 550 | | | University of New South Wales/Kirby Institute, University of New South Wales/Kirby Institute, Abbott, Merck Sharpe & Dohme, amfAR | Human Immunodeficiency Virus (HIV) -1 infection | | | | |
ACTRN12616001215415: The efficacy of pre-exposure prophylaxis for Human Immunodeficiency Virus (HIV) in high-risk individuals in Victoria, Australia |
|
|
| Recruiting | 4 | 2600 | | | The Alfred, Victoria State Government, health and Human Services, The Alfred, Victorian AIDS Council | HIV, Anxiety | | | | |
ACTRN12616001387415: NZ PrEP: A study assessing the feasibility,risks and benefits of prescribing daily Truvada in a sample of men who are at high risk of acquiring HIV |
|
|
| Recruiting | 4 | 150 | | | Auckland District Health Board, Gilead Sciences | HIV | | | | |
ChiCTR-OPC-15006528: Monitoring of Antiviral Therapy Indicators and Optimizing Treatment Management Model |
|
|
| Recruiting | 4 | 250 | | HIV-RNA viral load test (quantitative), immunology, blood routine and hepatorenal function test (quantitative) will be performed 0, 3, 6 and 12 months after treatment initiation respectively. National first-line regimen will be applied: AZT/TDF+3TC+EFV/NVP ;HIV-RNA viral load test (quantitative), immunology, blood routine, and liver and hepatorenal function test (quantitative) will be performed 0, 3, 6 and 12 months after treatment initiation respectively. Optimized regimen will be applied: LPV/r 400/100mg BID+ 3TC 300 mg QD. ;According to current national guideline, HIV-RNA viral load test (quantitative) will be perfomed once a year; immunology, blood routine and hepatorenal function test (quantitative) will be performed 2-4 times each year. National first-line regimen will be applied: AZT/TDF+3TC+EFV/NVP. | 8th People's Hospital of Guangzhou; Level of the institution：, Cooperation with Abbvie Pharmaceutical Trading (Shanghai) Co., Ltd. and self-funding | AIDS | | | | |
| Recruiting | 4 | 50 | | Efavirenz 400mg orally daily versus 600mg orally daily, in combination with other anti-retrovirals, 4 months | School of Pharmacy, Chinese University of Hong Kong; Dr Leung Wai Shing, Take on all the responsibilities of sponsorship jointly with the primary sponsor, The Chinese University of Hong Kong | HIV infection | | | | |
ChiCTR-OPC-16009603: A preliminary study on the delivery of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) at high risk of HIV transmission through the application of a self-financed incentivized approach |
|
|
| Recruiting | 4 | 70 | | HIV prevention / Daily pre-exposure prophylaxis / truvada; Truvada tablet (Tenofovir 300 mg / Emtricitabine 200 mg), 1 tablet, 30 weeks, daily | Stanley Ho Centre for Emerging Infectious Diseases; Level of the institution：, Council for the AIDS Trust Fund | HIV infection | | | | |
ChiCTR1800016100: Pre-exposure prophylaxis with on-demand versus daily TDF/FTC in men who have sex with men at high risk of HIV infection – a crossover study |
|
|
| Not yet recruiting | 4 | 90 | | Truvada tablet (Tenofovir 300 mg / Emtricitabine 200 mg): 1 tablet daily versus 2 tablets before sex, and 1 tablet at 24 and then 48 hours afterwards, for 16 weeks | Stanley Ho Centre for Emerging Infectious Diseases; Level of the institution：, AIDS Trust Fund | HIV infection | | | | |
ChiCTR-TRC-09000407: Antivirus Therapy for Population with HIV, HCV and TB Co-infection Clinical Trial |
|
|
| Completed | 4 | 490 | | PEG-IFN-alpha-2a, ribavirin capsules ;HAART, PEG-IFN-alpha-2a, ribavirin capsules ;HAART, PEG-IFN-alpha-2a, ribavirin capsules ;HAART | Guangzhou 8th People's Hospital; Ministry of Science and Technology People's Republic of China, Ministry of Science and Technology of China | Population with HIV and HCV and TB | | | | |
ChiCTR-TRC-11001261: Traditional Chinese medicine for the Herpes Zoster in AIDS patients: a randomized control trial |
|
|
| Completed | 4 | 120 | | Basic treatment ;Basic treatment+TCM | Beijing Ditan Hospital; Beijing Ditan Hospital, The ministry of Finance, China | herpes zoster and AIDS | | | | |
ChiCTR-TRC-11001252: Traditional Chinese medicine for the drug eruption caused by anti-HIV medicine: a randomized control trial |
|
|
| Completed | 4 | 175 | | Basic treatment + TCM protocol + TCM protocol ;Basic treatment protocol Aocol A ;Basic treatment protocol B | Beijing Ditan Hospital; Beijing Ditan Hospital, The ministry of Finance, China | AIDS, drug eruption | | | | |
ChiCTR-TRC-11001253: Traditional Chinese medicine for the Dyslipidemia caused by highly active antiretroviral therapies (HARRT): a randomized control trial |
|
|
| Completed | 4 | 180 | | Basic treatment+TCM ;Basic treatment | Beijing Ditan Hospital; The Ministry of Health, The Ministry of Finance, China | AIDS, dyslipidemia | | | | |
ChiCTR-TRC-11001262: Traditional Chinese medicine for the lung infection in patients with AIDS: a randomized control trial |
|
|
| Completed | 4 | 180 | | Basic treatment+TCM ;Basic treatment | Beijing Ditan Hospital; The ministry of Health, China, The ministry of finance, China | AIDS, lung infection | | | | |
ChiCTR-TRC-11001242: Traditional Chinese medicine for the chronic diarrhea in AIDS patients: a randomized double-blinding control trial |
|
|
| Completed | 4 | 300 | | Routine treatment +mimics of Xielikang Capsule+Loperamide ;Routine treatment B+Jianpizhixie recipe+Loperamide mimics ;Routine treatment +mimics of Xielikang Capsule+Loperamide ;Routine treatment+Loperamide | Beijing Ditan Hospital; The Ministry of Health, The Ministry of Finance, The Ministry of Health, China | chronic diarrhea, AIDS | | | | |
ChiCTR-TRC-11001243: Traditional Chinese medicine for the HIV associated prurigo: a randomized control trial |
|
|
| Completed | 4 | 360 | | Basic treatment ;Basic treatment+TCM | Beijing Ditan Hospital; The ministry of Health, China, The ministry of Finance, China | AIDS, Prurigo | | | | |
ChiCTR-TRC-11001254: Traditional Chinese medicine for the adverse reaction of digestive system caused by highly active antiretroviral therapies (HARRT): a randomized control trial |
|
|
| Completed | 4 | 360 | | Basic treatment ;Basic treatment+TCM | Beijing Ditan Hospital; The ministry of Health, The ministry of finance, China | AIDS | | | | |
ChiCTR-TRC-11001260: Traditional Chinese medicine for the hematological toxic reaction caused by highly active antiretroviral therapies (HARRT): a randomized control trial |
|
|
| Completed | 4 | 390 | | Basic treatment+TCM ;Basic treatment | Beijing Ditan Hospital; Beijing Ditan Hospital, The ministry of finance, China | AIDS, hematological toxic reaction | | | | |
2010-023245-30: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Solution for injection, COPEGUS*168CPR RIV 200MG, PEGASYS*SC SIR 0,5ML 180MCG+AG | ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | Chonic hepatitis HCV-related | | | | |
2011-004935-30: Study “before-after”: Adherence Evaluation to antiretroviral therapy administered in two different ways Studio ''before-after'' di valutazione dell'aderenza di due diverse modalita' di somministrazione della terapia antiretrovirale |
|
|
| Ongoing | 4 | 400 | Europe | Film-coated tablet, EPIVIR*FL 30CPR RIV 300MG, VIREAD*30CPR 245MG, ZIAGEN*6BLISTER 10CPR 300MG, SUSTIVA*30CPR RIV 600MG BLIST, RETROVIR*60CPR 300MG, TRUVADA*30CPR RIV 200MG/245MG, KIVEXA*BL 30CPR RIV 600MG+300M, COMBIVIR*60CPR RIV 150MG+300MG, ATRIPLA*30CPR RIV600+200+245MG | U.L.S.S. 9 DI TREVISO, studio no profit, farmaci a carico del SSN | HIV infection Infezione da HIV, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2011-005270-35: Study of the effect of pregnancy on the concentrations of antiretroviral drugs in the blood of women with HIV infection Studio dell'effetto della gravidanza sulle concentrazioni dei farmaci antiretrovirali nel sangue di donne con infezione da HIV |
|
|
| Ongoing | 4 | 120 | Europe | Tablet, Capsule, soft, Capsule, hard, Film-coated tablet, VIRAMUNE*60CPR 200MG, COMBIVIR*FL 60CPR RIV, KALETRA*120CPR RIV 200MG+50MG, REYATAZ*60CPS 150MG, TRUVADA*30CPR RIV 200MG/245MG, PREZISTA*60CPR RIV 600MG, ISENTRESS*FL 60CPR RIV 400MG, NORVIR*FL 84CPS MOLLI 100MG | ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI, Istituto Superiore di Sanita' | HIV-1 infection Infezione da HIV-1, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2011-001982-42: A study of the effect of antiretroviral therapy and immunoglobulin on the HIV reservoir in Acute HIV Infection. |
|
|
| Ongoing | 4 | 10 | Europe | Octagam, Solution for infusion, Octagam | Guy's & St. Thomas' NHS Foundation Trust, Guy's & St. Thomas' Charity | Acute HIV Infection, Acute HIV Infection, Diseases [C] - Immune System Diseases [C20] | | | | |
2011-005581-37: Efficacy of Switching to Lopinavir/Ritonavir (Kaletra) in Improving Cognitive function in patients treated with Efavirenz (EFV) (SLICE Study) |
|
|
| Ongoing | 4 | 30 | Europe | Kaletra, Film-coated tablet, Kaletra | The Newcastle upon Tyne Hospitals NHS Foundation Trust, AbbVie Limited | Cognitive function and sleep pattern in HIV-1 patients, HIV-1 infection, Diseases [C] - Immune System Diseases [C20] | | | | |
2010-023625-38: Trial to investigating the effect of Maraviroc on movement of microbes across the gut wall in HIV-1 infected individuals who are receiving antiretroviral therapy |
|
|
| Ongoing | 4 | 10 | Europe | Film-coated tablet, Celsentri film-coated tablets | Guy's and St Thomas' NHS Foundation Trust, ViiV Healthcare UK Ltd. | HIV, HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2014-000496-64: Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study Supresión viral en el líquido cefalorraquídeo en pacientes con infección por VIH-1 que reciben tratamiento antirretroviral con atazanavir potenciado con ritonavir y lamivudina. Estudio SCALA |
|
|
| Ongoing | 4 | 10 | Europe | REYATAZ, NORVIR, LAMIVUDINA EFG | Dr. Daniel Podzamczer Palter. Hospital Univesitari de Bellvitge. Unidad de VIH., Hospital Universitari de Bellvitge - Unidad de VIH | HIV-1 infection Infección por el virus VIH-1, HIV-1 infection Infección por el virus VIH-1, Diseases [C] - Virus Diseases [C02] | | | | |
| Ongoing | 4 | 22 | Europe | Tivicay, Isentress, Truvada, Film-coated tablet, Tivicay, Isentress, Truvada | Imperial College London | Human Immunodificiency Virus, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-004015-36: Role of a switch to an once-daily regimen of antiretroviral therapy on HIV-DNA levels and immune activation. Effetti del passaggio a un regime HAART in unica somministrazione giornaliera sui livelli di HIV-DNA e dei livelli di attivazione immunitaria. |
|
|
| Ongoing | 4 | 30 | Europe | STRIBILD, Film-coated tablet, STRIBILD | AZIENDA OSPEDALIERA SAN PAOLO, Gilead Sciences S.r.l. | Human Immunodeficiency Virus (HIV-1) Infection Infezione da virus dell’immunodeficienza umana (HIV1), HIV virus Infection Infezione da virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002281-70: Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted darunavir (the AdvanZ-4 Trial). Reconstitución inmune en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3 que reciben un régimen de fármacos antirretrovirales basado en dolutegravir o darunavir/ritonavir. Estudio AdvanZ-4. |
|
|
| Ongoing | 4 | 108 | Europe | CoatedTablet600 mg de abacavir ( sulfate) 300 mg de lamivudine, PREZISTA 300 mg comprimidos recubiertos con película darunavir, Norvir 100 mg soft tablets, Triumeq, Coated tablet, Capsule, soft, Tablet, KIVEXA( Abacavir 600 mg/ Lamivudine 300 mg) recovered tablets, PREZISTA 300 mg recovered Tablets, NORVIR 100 mg soft Tablets, TRIUMEQ®: Lamivudine(3TC) 300 mg+ Abacavir(ABC) 600 mg + dolutegravir(DGT) 50 mg : 1 comprimido | Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare UK Limited 980 Great West Road Brentford Middlesex TW8 9GS Reino Unido | tratement HIV infection tratamiento de la infección por HIV, HIV infection infección por HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2015-000274-35: clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression. ENSAYO CLÍNICO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE DOS ESTRATEGIAS DE SIMPLIFICACIÓN BASADAS EN DOLUTEGRAVIR EN PACIENTES INFECTADOS POR VIH CON SUPRESIÓN VIROLÓGICA SOSTENIDA. |
|
|
| Ongoing | 4 | 450 | Europe | Lamivudine, Efavirenz, nevirapine, J05AX12, Coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Tivicay, Stribild, TRUVADA, KIVEXA, ZIAGEN, VIREAD, EMTRIVA, ATRIPLA, EVIPLERA, ISENTRESS, RAYATAZ, PREZISTA, KALETRA, NORVIR, INTELENCE, EDURANT, TRIUMEQ | Fundació Lluita contra la SIDA, Fundació Lluita contra la SIDA | Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH)., HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2013-004809-24: The role of Home packs of HIV PEPSE in High Risk Individuals |
|
|
| Ongoing | 4 | 140 | Europe | Film-coated tablet, Celsentri (Trial Arm A), Truvada (Trial Arm A), Celsentri (Trial Arm B), Truvada (Trial Arm B) | Guy's & St. Thomas' NHS Foundation Trust, Viiv Healthcare UK Ltd, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002569-32: HIV prevention for men who have sex with men using medication HIV preventie voor mannen die seks hebben met mannen met behulp van medicijnen |
|
|
| Ongoing | 4 | 370 | Europe | truvada, Tablet, Truvada | Academic Medical Center, PHSA | prevention of HIV infection HIV infectie preventie, prevention of HIV infection HIV infectie preventie, Health Care [N] - Environment and Public Health [N06] | | | | |
2014-004297-42: Effect of changing one medication (Atripla) to another (Eviplera) on functions of the brain and emotions Het effect van wisselen van het ene medicijn (Atripla) naar het andere medicijn (Eviplera) op de functies van de hersenen en emoties |
|
|
| Ongoing | 4 | 60 | Europe | Film-coated tablet, Eviplera, Atripla | UMC Utrecht, Gilead Sciences | neurocognitive and emotional functioning in HIV positive men using antiretroviral therapy neurocognitief en emotioneel functioneren bij HIV positieve mannen die antiretrovirale therapie gebruiken, brain functions and emotions with people infected with HIV who use anti-HIV medication. functies van het brein en emoties bij mensen geïnfecteerd met HIV die anti-HIV medicijnen gebruiken., Not possible to specify | | | | |
ChiCTR-TRC-14004908: Rilpivirine Versus Efavirenz with Tenofovir and lamivudine's use in treatment-naive adults with HIV-1 infection and injection drug use on Methadone maintenance treatment |
|
|
| Recruiting | 4 | 60 | | taking Rilpivirine RPV+TDF+3TC and methadone ;taking Rilpivirine RPV+TDF+3TC and methadone | Yunnan Provincial Infectious Disease Hospital; Yunnan Provincial Infectious Disease Hospital, Funded by Xian Janssen Pharmaceutical Ltd. | AIDS | | | | |
2014-002134-31: Maraviroc and cardiovascular risk in HIV+ patients. Maraviroc e rischio cardiovascolare in pazienti HIV+. |
|
|
| Ongoing | 4 | 40 | Europe | NA, NA, Film-coated tablet, Celsentri | Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario, Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario | HIV-1 infection. Infezione da HIV-1., HIV-1 HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
NCT01998178: Immune Response and Safety Study of Human Papillomavirus (HPV) Vaccine in HIV-infected Pre-adolescent in Kenya |
|
|
| Active, not recruiting | 4 | 180 | RoW | Quadrivalent HPV Vaccine, Gardasil | Kenyatta National Hospital, University of Washington, Merck | Genital Warts, Cervical Cancer | 08/15 | 12/15 | | |
ChiCTR-TRC-13003717: Study on Chinese medicine treatment of patients with abnormal lipid metabolism after HAART program |
|
|
| Completed | 4 | 286 | | Highly active antiretroviral therapy in combination lipid particles ;Highly active antiretroviral therapy in combination with placebo | China Academy of Chinese medical Sciences; Capital Medical University, Beijing Ditan Hospital, AIDS and viral hepatitis and other major infectious diseases major science and technology | HIV Acquired Immunodeficiency Syndrome | | | | |
2015-004524-65: Efficacy of a vaccine with nine subgroups against human papilloma virus in HIV infected sexually active men who have sex with men. Effekten af en vaccine indeholdende ni undergrupper mod humant papilloma virus hos HIV smittede seksuelt aktive mænd der har sex med mænd. |
|
|
| Ongoing | 4 | 80 | Europe | Gardasil 9, Suspension for injection | Department of Infectious Diseases, AIDS- Foundation, Odense University Hospital Research Foundation | The purpose of the study is to investigate the efficacy of a new nonavalent HPV vaccine in sexually active HIV-infected MSM. Formålet med forsøget er at undersøge effekten af en ny ni-valent HPV vaccine hos seksuelt aktive, HIV-smittede MSM., The purpose of the study is to investigate the effect of a new vaccine , which contains nine subgroups against human papilloma virus among sexually active HIV-infected men who have sex with men . Formålet med forsøget er at undersøge effekten af en ny vaccine, som indeholder ni undergrupper mod humant papilloma virus hos seksuelt aktive, HIV-smittede mænd der har sex med mænd., Diseases [C] - Virus Diseases [C02] | | | | |
2015-003278-34: A RANDOMIZED BIOEQUIVALENCE STUDY OF EFAVIRENZ GENERIC DRUG AND SUSTIVA® (TABLETS 600 mg) IN PATIENTS WITH HIV-1 STUDIO RANDOMIZZATO PER LA VALUTAZIONE DELLA BIOEQUIVALENZA TRA EFAVIRENZ GENERICO E SUSTIVA® ENTRAMBI IN COMPRESSE DA 600 MG IN PAZIENTI CON HIV-1 |
|
|
| Not yet recruiting | 4 | 40 | Europe | Efavirenz, SUSTIVA, non applicabile, Film-coated tablet, EFAVIRENZ MYLAN - 600 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PVDC/AL, SUSTIVA - 600 MG COMPRESSE FILM RIVESTITE 30 COMPRESSE IN BLISTER USO ORALE | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Mylan S.p.A. | Patients with HIV-1 Pazienti affetti da HIV-1, Patients with HIV-1 Pazienti affetti da HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
2004-002565-20: Food effect on antiviral activity of videx enteric-coated capsules |
|
|
| Ongoing | 4 | 40 | Europe | Videx 400, Videx 250, 63305, Videx, Videx | Asociación para el estudio de enfermedades infecciosas | Asymptomatic HIV Infection | | | | |
2004-002633-39: Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance (a multicenter prospective clinical study within the SHCS) SHCS-Projekt Nr. 408 |
|
|
| Ongoing | 4 | 5 | Europe | Epivir, 3TC, Epivir, Epivir | Prof. Dr. med. Milos Opravil, Universitätsspital Zürich | HIV patients with virological treatment failure due to multi-drug-resistant virus including 3TC resistance | | | | |
2004-004802-26: ESTUDIO DE LA INFLUENCIA DE LAS ESTATINAS EN LA REPLICACIÓN PLASMÁTICA DEL VIH EN PACIENTES CON INFECCION POR EL VIH-1 QUE INTERRUMPEN EL TRATAMIENTO ANTIRRETROVIRAL |
|
|
| Ongoing | 4 | 70 | Europe | Atorvastatina, Simvastatina, | Fundació Lluita contra la SIDA | Patients HIV infected | | | | |
2004-001403-35: Estudio abierto, multicéntrico y aleatorizado sobre la eficacia y seguridad de la reducción de dosis de estavudina en pacientes en tratamiento antirretroviral que incluye estavudina a dosis estándar con buen control virológico e inmunológico. |
|
|
| Ongoing | 4 | 284 | Europe | Zerit, Zerit, Zerit, Zerit | Doctor Pere Domingo | AIDS | | | | |
2005-000028-17: Eficacia virológica, inmunológica y trascendencia clínica del efecto de la lamivudina en pacientes portadores de la mutación M184V/I con fracaso terapéutico. |
|
|
| Ongoing | 4 | 312 | Europe | EPIVIR, COMBIVIR, TRIZIVIR, EPIVIR, COMBIVIR, TRIZIVIR, EPIVIR, COMBIVIR, TRIZIVIR, EPIVIR, COMBIVIR, TRIZIVIR | DAVID DALMAU | HIV INFECTION | | | | |
2005-004021-26: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. |
|
|
| Ongoing | 4 | 60 | Europe | Efavirenz, AZT/3TC, emtricitabine/tenofovir, SUSTIVA, COMBIVIR, TRUVADA, SUSTIVA, COMBIVIR, TRUVADA | University Hospital Birmingham | HIV | | | | |
2005-004430-41: Effect of food on the pharmacokinetic profile of saquinavir at steady state in HIV-infected patients treated with saquinavir/ritonavir 1000/100 mg b.i.d. |
|
|
| Ongoing | 4 | 24 | Europe | Saquinavir mesylate, Ritonavir, n/a, Invirase, Norvir, Invirase, Norvir | St Stephen\'s AIDS Trust | HIV | | | | |
2005-003411-75: Estudio sobre la utilización de levetiracetam en monoterapia en pacientes HIV-positivos con epilepsia |
|
|
| Ongoing | 4 | 20 | Europe | levetiracetam, ucb-L059, Keppra 500 / 1000 mg comprimidos con cubierta pelicular, Keppra 500 / 1000 mg comprimidos con cubierta pelicular | Fundación para la Investigación Biomédica del Hospital Clínico de San Carlos | Pacientes HIV-positivos con epilepsia | | | | |
2006-001243-55: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT in HIV coinfected patients |
|
|
| Ongoing | 4 | 230 | Europe | Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus | Miguel Santin Cerezales | Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV coinfected patients with high ALT levels | | | | |
2006-005609-76: EFFECT OF DIFFERENT MEALS ON THE PHARMACOKINETIC PROFILE OF SAQUINAVIR AT STEADY STATE IN HIV-INFECTED PATIENTS TREATED WITH SAQUINAVIR/RITONAVIR 1000/100 mg BID. |
|
|
| Ongoing | 4 | 24 | Europe | Invirse, Norvir, n/a, Norvir, Norvir | St Stephens Aids Trust | HIV | | | | |
2006-006174-19: A randomised, open label, phase IV comparative study to determine the effects on renal function of continuing treatment with tenofovir versus replacement with abacavir in HIV positive persons |
|
|
| Ongoing | 4 | 30 | Europe | Ziagen, Viread, Truvada, Kivexa, Not appllicable, Not applicable, Not appilcable, Ziagen, Viread, Truvada, Kivexa, Ziagen, Viread, Truvada, Kivexa | St Stephens AIDS Trust | HIV | | | | |
2006-006716-30: Randomized, controlled, multicentric trial to evaluate efficacy and safety of the switch from a LPV/r based therapy to an ATV/r or a NVP based treatment in association with ABC/3TC, in HIV patient with undetectable viral load Randomized, controlled, multicentric trial to evaluate efficacy and safety of the switch from a LPV/r based therapy to an ATV/r or a NVP based treatment in association with ABC/3TC, in HIV patient with undetectable viral load |
|
|
| Ongoing | 4 | 200 | Europe | VIRAMUNE*60CPR 200MG, REYATAZ*60CPS 150MG, KIVEXA*BL 30CPR RIV 600MG+300M, NORVIR*4FL 84CPS MOLLI 100MG, KALETRA*BLIST 180CPS MOLLI, VIRAMUNE*60CPR 200MG, REYATAZ*60CPS 150MG, KIVEXA*BL 30CPR RIV 600MG+300M, NORVIR*4FL 84CPS MOLLI 100MG, KALETRA*BLIST 180CPS MOLLI | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | HIV infection Infezione da HIV | | | | |
2006-003425-81: Host genetic factors influencing drug disposition and response to HIV treatment |
|
|
| Ongoing | 4 | 500 | Europe | Protease inhibitor, Nucleoside and nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Protease inhibitors, Nucleoside and nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Protease inhibitors, Nucleoside and nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors | University of Liverpool | Pharmacogeneric study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will be carried out and choice of antiretroviral and their dosing will not be influenced by participation in this study. | | | | |
2006-006076-38: The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure |
|
|
| Ongoing | 4 | 12000 | Europe | Protease inhibitor, Nucleoside and nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Protease inhibitors, Nucleoside and nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Protease inhibitors, Nucleoside and nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors | University of Liverpool, Royal Liverpool & Broadgreen University Hospitals Trust | Pharmacogenetic study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will be carried out and choice of antiretroviral and their dosing will not be influenced by participation in this study. | | | | |
2006-006156-36: Papel de los niveles plasmáticos de fitosterol en la predicción del efecto hipolipemiante de la ezetimiba en sujetos infectados por VIH que reciben inhibidores de la proteasa.ROLE OF PHYTOSTEROL PLASMA LEVELS IN PREDICTING THE LIPID LOWERING EFFECT OF EZETIMIBE IN HIV INFECTED SUBJECTS RECEIVING PROTEASE INHIBITORS |
|
|
| Ongoing | 4 | 20 | Europe | Ezetrol, Ezetrol | Hospital Clinic, Barcelona | Infección crónica por VIHHipercolesterolemiaChronic HIV infectionhypercholesterolemia | | | | |
2006-006297-23: A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy |
|
|
| Ongoing | 4 | 10 | Europe | Kaletra 200mg/50mg film coated tablets, NA, Kaletra tablets, Kaletra tablets | Guy\'s & St Thomas\' NHS Foundation Trust | HIV during pregnancy | | | | |
2007-000932-19: A phase IV study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppression on highly active antiretroviral therapy (HAART) |
|
|
| Ongoing | 4 | 20 | Europe | Darunavir, Ritonavir, Prezista, Norvir, Prezista, Norvir | St Stephen\'s AIDS Trust | HIV | | | | |
2007-007018-12: “Estudio prospectivo, abierto, aleatorizado y cruzado sobre el efecto de la Hidroxicloroquina, 200mg al día, en factores inflamatorios y metabólicos relacionados con la enfermedad cardiovascular en pacientes infectados por el virus de la inmunodeficiencia humana.” \"Open label, prospective, randomized, crossed study of the effect of Hidroxychloroquine, 200 mg QD, on inflammatory and metabolic factors related to cardiovascular disease in human immunodeficiency virus infected patients\" |
|
|
| Ongoing | 4 | 120 | Europe | Dolquine, Dolquine | Carlos Alonso-Villaverde Lozano, Hospital Universitari Sant Joan de Reus | Infección por el virus de la inmunodeficiencia adquirida | | | | |
2008-002978-35: Intensification of HAART with Maraviroc (MVC) as first line therapy of HIV-1-infected patients to rapidly suppress viral replication and minimize the evolution of drug-resistant variants |
|
|
| Ongoing | 4 | 20 | Europe | MARAVIROC, | AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | First line therapy of HIV-1-infected patients. | | | | |
2008-003635-20: Maraviroc Immune Recovery Study (MIRS):A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery |
|
|
| Ongoing | 4 | 130 | Europe | Celsentry, Celsentry | Universitair Medisch Centrum Utrecht | HIV-1 infection | | | | |
2007-006277-92: Treatment of anal intraepithelial neoplasia in HIV-positive patients, a triple-arm randomized clinical trial |
|
|
| Ongoing | 4 | 150 | Europe | Imiquimod, Fluorouracil, Aldara, Efudix, Aldara, Efudix | Academic Medical Center, department of infectious diseases | anal intraepithealial neoplasia in HIV-positive patients | | | | |
2008-006371-67: EFFECT OF THIENOPYRIDINE DERIVATIVE (CLOPIDOGREL) ON THE DISPOSITION OF EFAVIRENZ AND NEVIRAPINE IN HIV POSITIVE PATIENTS |
|
|
| Ongoing | 4 | 37 | Europe | plavix, Nevirapine, Efavirenz, B01AC04, J05AG03, Plavix (Sanofi Synthelabo, Guildford, United Kingdom), viramune, sustiva;stocrin, Plavix (Sanofi Synthelabo, Guildford, United Kingdom), viramune, sustiva;stocrin | Royal Liverpool and Broadgreen University Hospital, University of Liverpool | To determine whether anti-platelet agent clopidigrel influences the disposition of NNRTIs (efavirenz and nevirapine) | | | | |
2009-014694-40: A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy |
|
|
| Ongoing | 4 | 12 | Europe | | | HIV | | | | |
2009-011816-39: A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects.‘The First Failure Study’ : ‘FAST’ |
|
|
| Ongoing | 4 | 44 | Europe | Etravirine, Darunavir, Truvada, Ritonavir, Intelence, Prezista, Truvada, Norvir, Intelence, Prezista, Truvada, Norvir | Imperial College London | HIV | | | | |
2010-023264-40: Efficacy in the central nervous system (CNS) of two combination regimens with different penetration rank in HIV-positive na�ve patients |
|
|
| Ongoing | 4 | 32 | Europe | KALETRA, KIVEXA, REYATAZ, TRUVADA, NORVIR, KALETRA, KIVEXA, REYATAZ, TRUVADA, NORVIR | AZIENDA OSPEDALIERA S. GERARDO DI MONZA | HIV infection | | | | |
2010-022120-72: The impact of a new single therapy (Darunavir/ritonavir) on metabolism after successfully suppressing the virus with the normal treatment (Atripla) for HIV-1-infected patients (MIDAs). |
|
|
| Ongoing | 4 | 70 | Europe | Prezista, Norvir, Atripla, Prezista, Norvir, Atripla | Guy\'s & St. Thomas\' NHS Foundation Trust, Tibotec (a division of Janssen-Cilag Ltd) | HIV | | | | |
2010-023192-26: EFFECT OF SWITCHING FROM NRTIS TO MARAVIROC ON NRTI-ASSOCIATED MITCHONDRIAL TOXICITY AND IMMUNE ACTIVATION Auswirkung des Wechsels von NRTIs zu Maraviroc auf NRTI-assoziierte mitochondriale Toxizität und Immunaktivierung |
|
|
| Ongoing | 4 | 80 | Europe | Celcentri, Celcentri, Celcentri | mib Dienstleistungsgesellschaft mbH, ViiV Healthcare GmbH | Increases in inflammatory biomarkers have been associated with various non-AIDS complications such as cardiovascular events. Maraviroc has no known toxic effects on mitochondria and has been shown to reduce immune activation / inflammation in treatment intensification settings. The purpose of this study is to investigate if switching from NRTIs to Maraviroc results in reversal of NRTI-associated mitochondrial toxicity and decreases in markers of immune activation and inflammation. | | | | |
2010-022775-57: This is a pilot study to see how giving HIV infected patients, who have Vitamin D deficiency (and are already taking standard therapy) a high dose of vitamin D will affect the levels of vitamin D in their bodies and if this will help them have a better immune response to their infection. |
|
|
| Ongoing | 4 | 40 | Europe | Adcal-D3 Lemon Chewable Tablets, Adcal-D3 Lemon Chewable Tablets | Guy\'s and St Thomas\' NHS Foundation Trust, Tibotec (a division of Janssen-Cilag Ltd), | HIV infected patients with vitamin D defficiency | | | | |
| Ongoing | 4 | 10 | Europe | INTELENCE 100 mg comprimidos, INTELENCE 100 mg comprimidos | Servicio de Enfermedades Infecciosas. Unidad VIH. Hospital Universitari de Bellvitge, HOSPITAL DE BELLVITGE | HIV | | | | |
2010-023122-21: This study aims to look at the effect of a high dose of Vitamin D on bone mineral density in HIV patients |
|
|
| Ongoing | 4 | 48 | Europe | Dekristol, Dekristol | King\'s College London, Guy\'s and St. Thomas\' NHS Foundation Trust, Viiv Healthcare Ltd | HIV | | | | |
2011-003447-21: Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis |
|
|
| Ongoing | 4 | 280 | Europe | Maraviroc, Celsentri, Celsentri | Camden Provider Services, Pfizer | Prophylaxis and prevention of HIV Infection. | | | | |
2012-000649-11: SSAT046 Addition of Maraviroc to monotherapy Darunavir/Ritonavir study |
|
|
| Ongoing | 4 | 30 | Europe | Darunavir, Ritonavir, Maraviroc, Prezista, Norvir, Celsentri, Prezista, Norvir, Celsentri | St Stephen\'s Aids Trust, St Stephen\'s AIDS Trust, Pfizer Inc | HIV | | | | |
2012-001142-18: Efficacy and pharmacokinetics of a switch from a regimen consisting of emtricitabine, nevirapine and tenofovir to rilpivirine, emtricitabine and tenofovir in virologically suppressed HIV-1 infected patients. Werkzaamheid en farmacokinetiek van rilpivirine in HIV-1 positieve patiënten waarin het HIV onderdrukt is door een behandeling met emtricitabine, nevirapine en tenofovir en die deze behandeling vervangen door rilpivirine, emtricitabine en tenofovir. |
|
|
| Ongoing | 4 | 50 | Europe | Eviplera, J05AR08, Eviplera, Eviplera | Erasmus MC, Gilead | HIVAIDS | | | | |
2012-002663-10: Darunavir/ritonavir and rilpivirine in therapy-naïve patients. |
|
|
| Ongoing | 4 | 40 | Europe | Edurant (rilpivirine), Prezista (darunavir), Norvir (ritonavir), Edurant, Prezista, Norvir, Edurant, Prezista, Norvir | St Stephen\'s AIDS Trust, Janssen-Cilag Ltd | HIV-1 | | | | |
2012-003595-39: A clinical trial to compare brain function and neurocognitive performance in antiretroviral treatments with different levels of penetration in the central nervous system. Ensayo clínico para comparar el funcionamiento cerebral y rendimiento neurocognitivo en tratamientos antirretrovirales con distintos niveles de penetracion en el sistema nervioso central. |
|
|
| Ongoing | 4 | 40 | Europe | ATAZANAVIR, Reyataz, Norvir, Kivexa, Sustiva, Truvada, Reyataz, Norvir, Kivexa, Sustiva, Truvada | Fundación para la Investigación Biomédica del Hospital Universitario La Paz, Fundacion para la Investigacion Biomédica del Hospital Universitario La Paz | Patients infected with human immunodeficiency virus who have never received antiretroviral treatment. Pacientes infectados con virus de inmunodeficiencia humana que nunca han recibido tratamiento antirretroviral. | | | | |
2012-003778-16: The dose and genital tract concentration of Maraviroc needed for protection from HIV infection |
|
|
| Ongoing | 4 | 54 | Europe | Celsentri, Celsentri | Guy\'s & St. Thomas\' NHS Foundation Trust, Pfizer Inc | HIV | | | | |
2013-002009-70: HPV vaccination after treatment of anal intraepithelial neoplasia HPV vaccinatie na behandeling van anale dysplasie |
|
|
| Ongoing | 4 | 125 | Europe | Gardasil, Gardasil | Academic Medical Center, The Netherlands Organisation for Health Research and Development | Intra-anal high-grade anal intraepithelial neoplasia (AIN) (grade 2-3) in HIV+ men that was successfully treated in the past year with conventional cauterization, cryotherapy, or other forms of local treatment. | | | | |
2013-003359-39: Treatment with Zoledronic acid or Tenofovir Switching in HIV-Infected Tratamiento con ácido zoledrónico vs sustitución de tenofovir en pacientes infectados por el VIH |
|
|
| Ongoing | 4 | 28 | Europe | Aclasta, Aclasta | Fundació ClÃnic per a la Recerca Biomèdica, St. Vicent's Hospital | low bone mineral density - HIV Baja densidad mineral ósea - VIH | | | | |
| Ongoing | 4 | 112 | Europe | Dolutegravir, Darunavir, Atazanavir, Kaletra, Ritonavir, Fosamprenavir, INVIRASE, Tivicay, Prezista, Reyataz, Kaletra, Norvir, Telzir, Invirase, Tivicay, Prezista, Reyataz, Kaletra, Norvir, Telzir, Invirase | St Stephen\'s AIDS Trust, NEAT-ID, Viiv Healthcare Ltd | HIV infection | | | | |
| Completed | 4 | 130 | | tenofovir + lamivudine + efavirenz ;no | China Medical University; Level of the institution：, mega-projects of national science research for the 12th Five-Year Plan (2012ZX10001-006) | HIV infection | | | | |
2015-005297-37: Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq |
|
|
| Ongoing | 4 | 90 | Europe | Tenofovir, Lamivudine, Efavirenz, Nevirapine, Etravirine, Rilpivirine, Film-coated tablet, Tablet, Triumeq, Truvada, Atripla, Eviplera | King's College Hospital NHS Foundation Trust, ViiV Healthcare Ltd | Human Immunodeficiency Virus, People infected with Human Immunodeficiency Virus (HIV), Diseases [C] - Immune System Diseases [C20] | | | | |
2012-000198-21: A study to assess the efficacy and safety of the withdrawal of nucleos/tide analogues with resistance in multitreated HIV-1-infected subjects with virological suppression ESTUDIO SOBRE LA EFICACIA Y SEGURIDAD DE LA RETIRADA DE ANÁLOGOS DE NUCLEÓS/TIDO CON RESISTENCIA EN SUJETOS CON INFECCIÓN POR VIH-1 MULTITRATADOS Y CON SUPRESIÓN VIROLÓGICA. |
|
|
| Ongoing | 4 | 292 | Europe | Epivir, Emtriva, Retrovir, Zerit, Viread, Ziagen, Combivir, Trizivir, Kivexa, Truvada, Videx, Epivir, Emtriva, Retrovir, Zerit, Viread, Ziagen, Combivir, Trizivir, Kivexa, Truvada, Videx | Fundació Lluita contra la SIDA, Ministerio de Sanidad, Política Social e Igualdad (Investigación Independiente) | Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH). | | | | |
2016-001371-69: Tenofovir DP concentrations in seminal cells and semen quality in HIV-1 infected patients receiving a TAF containing regimen Concentraciones de Tenofovir DP en células seminales y calidad del semen en pacientes infectados por el virus VIH-1 que reciben un régimen que contenga TAF |
|
|
| Ongoing | 4 | 15 | Europe | Coated tablet, Genvoya | Fundació Lluita contra la SIDA, Gilead Sciences S.L. | HIV-1 positive patients Pacientes VIH-1 positivos, HIV-1 positive patients Pacientes VIH-1 positivos, Diseases [C] - Virus Diseases [C02] | | | | |
2016-002006-39: Study on Efficacy and safety of switch ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a HIV infection Studio sull¿ Efficacia e la sicurezza di passaggio a ElvitegraviR/cobicistat/emtricitabina/tenofovir alafenamide (E/C/F/TAF) in pazienti con infettati dal virus HIV |
|
|
| Not yet recruiting | 4 | 30 | Europe | Film-coated tablet, Genvoya | ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI", Gilead Sciences | Treatment of HIV infection Trattamento dell¿ infezione da HIV, Treatment of HIV infection Trattamento dell¿ infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003345-29: Safety of tenofovir alafenamide (TAF) in patients who developed kidney toxicity while receiving tenofovir disoproxil fumarate (TDF) |
|
|
| Ongoing | 4 | 40 | Europe | Film-coated tablet, Descovy | Kings College Hospital NHS Foundation Trust, Gilead Sciences | HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002284-15: A study to assess changes in Central Nervous System (CNS) function where no obvious symptoms exist, when switching from Atripla to Eviplera switch in HIV infected patients |
|
|
| Not yet recruiting | 4 | 40 | Europe | Eviplera, Film-coated tablet, Eviplera | St Stephen's AIDS Trust, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 4 | 60 | Europe | Tivicay 50 mg film - coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets, Film-coated tablet, Tivicay 50 mg film-coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets | St Stephen's AIDS Trust, Merck, Sharp & Dohme Limited | HIV | | | | |
2016-005078-37: A study to reduce the risk of sexually acquired HIV-1 in adults at high risk. |
|
|
| Ongoing | 4 | 100 | Europe | Truvada (emtricitabine and tenofovir disoproxil fumarate), Truvada(emtricitabine&tenofovirdisoproxil fumarate, Film-coated tablet, Truvada | Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases, Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases | Healthy volunteers, Healthy volunteers, Diseases [C] - Virus Diseases [C02] | | | | |
| Ongoing | 4 | 64 | Europe | Triumeq, Genvoya, Tablet, Triumeq, Genvoya | Fundación SEIMC-GESIDA, GILEAD Sciencies S.A. | HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
| Not yet recruiting | 4 | 186 | NA | Placebo for MVC, Maraviroc, MVC, Placebo for DTG, Dolutegravir, DTG | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection | 06/17 | 06/18 | | |
2017-000469-62: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients. DGT-SOT Ensayo clínico piloto de un brazo para evaluar la eficacia, las interacciones farmacocinéticas y la seguridad del dolutegravir más 2 inhibidores nucleósidos de la Transcriptasa Inversa (NRTIs en su siglas en inglés) en pacientes trasplantados de órganos sólidos infectados por el VIH-1. DGT-SOT |
|
|
| Ongoing | 4 | 20 | Europe | Triumeq 50 mg/600 mg/300 mg comprimidos recubiertos con película dolutegravir/abacavir/lamivudina, Tivicay 50 mg, Truvada comprimidos recubiertos con película., Coated tablet, Tablet, Triumeq®, Dolutegravir 50 mg, 200 mg de emtricitabina y 245 mg de tenofovir disoproxil (equivalente a 300 mg de tenofovir disoproxil fumarato ó 136 mg de tenofovir). | Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare | HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., Diseases [C] - Virus Diseases [C02] | | | | |
2017-002385-49: IN-UK-311-3956: A Feasibility Study of the Switch of Tenofovir disoproxil fumarate to Tenofovir alafenamide fumarate and the Effect on Kidney Function in individuals infected with both Chronic Hepatitis B and HIV. |
|
|
| Not yet recruiting | 4 | 20 | Europe | Descovy 200/10mg, Descovy 200/25mg, Film-coated tablet, Descovy 200/10mg, Descovy 200/25mg | King's College Hospital NHS Foundation Trust, Gilead Sciences International Ltd | HIV and Hepatitis B, HIV and Hepatitis B infections, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-002855-27: BonE health in ageING Women: Improvement or prevention of changes in Bone MineralDensity by Switching Antiretroviral Agents. Is there an optimal time to intervene? La salute delle ossa nell¿invecchiamento femminile: miglioramento o prevenzione delle variazioni di densit¿ minerale ossea modificando i farmaci antiretrovirali. Esiste un momento ottimale per intervenire? |
|
|
| Not yet recruiting | 4 | 128 | Europe | truvada, stribild, eviplera, genvoya, descovy, Odefsey, J05AR03, eviplera, J05AR18, J05AR17, J05AR19, Film-coated tablet, TRUVADA - 30 COMPRESSE RIVESTITE CON FILM IN FLACONE HDPE DA 200 MG/245 MG, STRIBILD - 150MG/150MG/200MG/245MG/ - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EVIPLERA - 25MG RILPIVIRINA/200MG EMTRICITABINA/245MG TENOFOVIR DISOPROXIL-COMPRESSA RIVESTITA CON FILM-USO ORALE-FLACONE (HDPE) 30 COMPRESSE, GENVOYA - 150 MG / 150 MG / 200 MG /10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE | UNIVERSITY HEALTH NETWORK, Gilead Sciences, Canadian HIV Trials Network | HIV infection and menopause infezione da HIV e menopausa, HIV infection and menopause infezione da HIV e menopausa, Diseases [C] - Virus Diseases [C02] | | | | |
2017-004137-91: A single-arm, open-label, multicenter phase IV trial to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alfa-namide as first-line treatment in naïve patients with HIV-1 infection with severe immunosuppression Estudio fase IV, abierto, multicéntrico, de un único brazo para evaluar la eficacia y seguridad de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida como tratamiento de primera línea en pacientes naïve con infección por VIH-1 con inmunosupresión severa |
|
|
| Ongoing | 4 | 50 | Europe | Tablet, Genvoya | Fundacion SEIMC-GESIDA, Gilead | AIDS SIDA, AIDS SIDA, Diseases [C] - Virus Diseases [C02] | | | | |
2017-004141-24: A study in which people who have HIV and fatty liver disease, who do not drink excessive alcohol, are either asked to take the drug maraviroc on top of their normal anti-HIV medicines or to take their normal anti-HIV medicines alone |
|
|
| Ongoing | 4 | 60 | Europe | Celsentri, Film-coated tablet, Celsentri | Brighton and Sussex University Hospitals NHS Trus | Non-alcoholic fatty liver disease in people living with well-controlled HIV-1 infection, A disease of too much fat laid down in the liver in people who have HIV and do not drink over the recommended limit of alcohol, Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-000215-24: A trial to evaluate the immunogenicity of vaccine against human papillomavirus in HIV-infected men who have sex with men. GESIDA 10017 Study Ensayo clínico sobre la inmunogenicidad de la vacuna frente al virus del papiloma humano en hombres infectados por el VIH que tienen sexo con hombres. Estudio GESIDA 10017 |
|
|
| Ongoing | 4 | 166 | Europe | Suspension for injection in pre-filled syringe, Gardasil 9 | Fundacion SEIMC-GESIDA, Merck Sharp & Dohme | AIDS SIDA, AIDS SIDA, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-001645-14: Study to compare two treatments in patients who have never taken HIV medication randomized in different centers in Spain. (The Symtri study) Estudio para comparar dos tratamientos en pacientes que nunca han tomado medicación para el VIH asignados al azar realizado en diferentes centros de España. (Estudio SYMTRI) |
|
|
| Ongoing | 4 | 316 | Europe | Film-coated tablet, Symtuza, Triumeq | Spanish HIV/AIDS Research Networkº, Spanish HIV/AIDS Research Network | HIV infection Infección por VIH, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2016-000437-43: The time to protection and adherence requirements of Raltegravir with or without lamivudine in protection from HIV infection |
|
|
| Not yet recruiting | 4 | 36 | Europe | Raltegravir, Lamivudine, Tablet, Film-coated tablet, Raltegravir, Lamivudine | Guy's and St Thomas NHS Foundation Trust, Merck Sharp & Dhome Ltd | HIV, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |